Group B meningococcal vaccine science and policy

Simon B Drysdale; Andrew J Pollard

doi:10.1016/j.jinf.2015.04.021

Group B meningococcal vaccine science and policy

J Infect. 2015 Jun:71 Suppl 1:S15-20. doi: 10.1016/j.jinf.2015.04.021. Epub 2015 Apr 24.

Authors

Simon B Drysdale¹, Andrew J Pollard²

Affiliations

¹ Oxford Vaccine Group, Department of Paediatrics, University of Oxford, United Kingdom; NIHR Oxford Biomedical Research Centre, Level 2, Children's Hospital, Oxford OX3 9DU, United Kingdom. Electronic address: [email protected].
² Oxford Vaccine Group, Department of Paediatrics, University of Oxford, United Kingdom; NIHR Oxford Biomedical Research Centre, Level 2, Children's Hospital, Oxford OX3 9DU, United Kingdom. Electronic address: [email protected].

PMID: 25917798
DOI: 10.1016/j.jinf.2015.04.021

Abstract

Capsular group B Neisseria meningitidis is one of the leading causes of death in developed countries. A new vaccine (4CMenB) has recently been developed which was found to have an acceptable safety profile in clinical studies and to be immunogenic. This review examines the evidence supporting the licensure of the 4CMenB vaccine and discusses recommendations for its use.

Keywords: Capsular group B Neisseria meningitidis; Capsular group C Neisseria meningitidis; Children; Immunogenicity; Infant; Reactogenicity; Vaccine.

Publication types

Review

MeSH terms

Adolescent
Adult
Child
Child, Preschool
Humans
Infant
Infant, Newborn
Meningococcal Infections* / epidemiology
Meningococcal Infections* / microbiology
Meningococcal Infections* / prevention & control
Meningococcal Vaccines* / administration & dosage
Meningococcal Vaccines* / adverse effects
Meningococcal Vaccines* / immunology
Middle Aged
Neisseria meningitidis, Serogroup B / immunology*
Young Adult

Substances

4CMenB vaccine
Meningococcal Vaccines